Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models Background: In metastatic renal cell cancer (mRCC), the Memorial Sloan-Kettering Cancer Center (MSKCC) risk model is widely used for clinical trial design and patient management. To improve prognostication, we applied proteomics to identify novel serological proteins associated with overall survival (OS).
Given the highly variable disease course and various treatment drawbacks, it is important to a priori select patients who clearly benefit from therapy. To date, the Memorial SloanKettering Cancer Center (MSKCC) risk model [2] is the most widely used prognostic classification system for patient management and clinical trial design. This model originally included five prognosticators of poor survival: low Karnofsky performance status (KPS < 80%), elevated lactate dehydrogenase (LDH), decreased hemoglobin, raised 'corrected' calcium and absence of prior nephrectomy [7] . Using these factors, patients can be categorized into three prognostic groups (favorable, intermediate or poor) differing in overall survival (OS). In 2002, Motzer et al. [2] refined this model interchanging absence of prior nephrectomy with time between diagnosis and start of systemic treatment and the model is currently widely used as the MSKCC criteria for mRCC patient prognostication. At the Cleveland Clinic, these MSKCC criteria were further validated and expanded with the number of metastatic sites (£1 versus ‡2) and prior radiotherapy [8] . Although recent years have demonstrated the value of MSKCC criteria in patient management, this model could be refined.
The objective of this large retrospective cohort study among mRCC patients was to associate novel serum proteins with survival by applying a proteomics-based approach, surfaceenhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS). Proteomic results were validated using enzyme-linked immunosorbent assays (ELISAs) and immunoturbidimetry. We identified a protein signature that could accurately predict survival. Finally, we investigated whether addition of novel proteins significantly improved the predictive accuracy of the traditional risk factors in the MSKCC model.
patients and methods sample collection and survival
Serum samples from 114 consecutive RCC patients with metastasis were collected (2001) (2002) (2003) (2004) (2005) (2006) at three Dutch cancer institutes: the University Medical Center Utrecht (n = 63), The Netherlands Cancer Institute (n = 29) and the Erasmus Medical Center Rotterdam (n = 22). Each patient provided informed consent before blood withdrawal as stipulated by the three institutional ethical boards and the patients were enrolled in different study protocols. Blood was obtained by venapuncture, coagulated at room temperature (0.5-6 h), centrifuged (1500-1900 g) and frozen (71% at 280°C; 29% at 230°C). In 16% of the study cohort (18 mRCC patients), blood samples were collected before primary tumor resection. Blood of 81 (71%) patients was drawn at start of first-line systemic treatment. In 7% of the cases (eight patients), blood samples were gathered at start of secondline therapy. Clinical features, disease characteristics and baseline biochemical parameters were gathered from medical records, including MSKCC risk factors. OS was defined as the time from blood collection to the date of death or last follow-up.
screening and validation methods: serum protein profiling
Serum was screened to discover protein profiles using the semiquantitative SELDI-TOF MS (Ciphergen Biosystems Inc., Freemont, CA) as reported by Won et al. [9] and validated in our laboratory [10] . Detailed assay procedures are described in Appendix 1. Subsequently, apolipoprotein A2 (ApoA2) was quantified by immunoturbidimetry using the nephelometer BN-II system (Dade Behring Inc., Newark, NJ). ELISA kits quantified serum amyloid alpha (SAA; Tridelta Development Ltd, Kildare, Ireland) and transthyretin (TTR; Immundiagnostik AG, Bensheim, Germany) levels according to manufacturer's instructions.
statistics and bioinformatics
ProteinChip Software package, version 3.1 (Ciphergen Biosystems), was used to analyze entire protein profiles. Spectra were baseline subtracted and normalized to the total ion current. Spectra with normalization factors >2.00 or <0.50 were excluded. SELDI-TOF MS intensities were authenticated as mass peaks when signal to noise ratio was ‡5, mass accuracy window £1% and presence ‡30% of all spectra. Mass peak intensities were used as continuous variables for association with survival. Statistical significance was considered as P <0.05.
Univariable Cox proportional hazards (PH) regression analysis was applied to associate validated proteins and MSKCC criteria to survival. Subsequently, to derive a model on the basis of validated protein signatures, all variables were dichotomized and multivariable Cox PH regression analysis was applied with backward stepwise selection.
Multivariable Cox PH regression analysis was used to test whether novel prognostic proteins improved the accuracy of the MSKCC model and subsequently, a backward stepwise selection procedure was applied to design a novel protein-based model. Akaike's Information Criteria (AIC) and R 2 were used to compare the accuracy of survival prediction of the MSKCC model with our novel protein-based models [11, 12] . The lower the AIC, the better the predictive model fits the data. Kaplan-Meier curves described the predictive accuracy of various prognostic models.
To prevent overoptimistic predictive accuracy, we applied bootstrapping techniques to internally validate and estimate the optimism R 2 in our prognostic models to correct for overestimation [11, 13] , repeating the entire estimation process in each bootstrap sample 500 times. R 2 is a measure for the proportion variability explained by the model and the predictive strength of the model. The optimism of our novel models is the bias due to overfitting of the data. The R 2 of the original model is adjusted by the optimism to obtain the corrected R
2
, which better reflects the estimated probability of our findings when applied in a subsequent validation studies. Statistical analysis was carried out using SPSS (version 15.0) and R software (version 2.3.1).
results

patient characteristics
Detailed characteristics of 114 patients are depicted in Table 1 . All patients were planned to receive interferon-based treatment in clinical trials. However, some patients were only screened but did not receive systemic treatment due to ineligibility or performance status. In total, 89 patients (78%) received firstline systemic therapy for mRCC, principally interferon-based therapy (83 patients, 73%). Blood collection was generally carried out before start of first systemic therapy (81 patients, 71%); however, in 8 patients, blood was sampled after first-line treatment with interferon but before second-line therapy. The other 25 patients (22%) received either palliative care (21 patients) or were followed without interventions (4 patients) because of stable disease. After first-line treatment, 39 patients (34%) received second-line systemic therapy consisting of small molecules. Hemoglobin: lower limits of reference range for men and women were 13.5 and 12.0 g/dl, respectively. CNS, central nervous system; CI, confidence interval; SD, standard deviation; IQR, interquartile range; LLN, lower limit of laboratory's reference range; ULN, upper limit of laboratory's reference range; IFN, interferon. Protein profiles of all patients were generated in two independent experiments and individual serum samples were assessed five times. The first experiment was carried out in duplicate and resulted in 25 distinct mass peaks. To determine the robustness of the obtained data, the complete sample set was reanalyzed in triplicate. Freshly thawed serum samples were measured within 3 weeks to minimize laser intensity variation. This second experiment detected 31 distinct mass peaks (supplemental Table S1 , available at Annals of Oncology online) in which 25 mass peaks were identical to the first experiment, indicating that the data obtained by SELDI-TOF MS were highly reproducible. Of these detected mass peaks, 17 are known proteins [14] . Univariable Cox regression analysis for all 31 mass peaks identified 10 proteins related to survival. For illustration, representative protein spectra of mass peaks (zoomed in) are shown for two patients with poor and favorable survival (Figure 1 ). Mass peaks with corresponding mass : charge (M : z) ratios of 8.6, 11.7 and 13.7 kDa were selected for further investigation in the subsequent analysis because (i) they were strongly associated to survival, (ii) they are known proteins [14, 15] , namely apolipoprotein-A2 (ApoA2), SAA and TTR, respectively, and (iii) conventional quantification techniques for these proteins were available for subsequent validation.
validation method: ApoA2, SAA and TTR associated with survival
Concentrations of ApoA2, SAA and TTR were measured by conventional antibody-directed quantification methods. The continuous variables ApoA2, SAA and TTR significantly predicted patient survival (P = 5.5 · 10 29 , 1.1 · 10 27 and 0.0004, respectively; Table 3 ). The positive regression coefficient for SAA indicated that higher SAA levels were associated with reduced survival, whereas negative regression coefficients for ApoA2 and TTR designated prolonged survival for higher concentrations.
two-protein signature accurately predicts survival
Including the three validated proteins in multivariable Cox PH regression analysis revealed a prognostic model with ApoA2 and SAA. TTR was excluded because it did not significantly improve the ApoA2/SAA model. When SAA levels were not elevated, low quantities of ApoA2 were highly prognostic for poor survival. Therefore, we used the combination of the lowest two tertiles for ApoA2 and the highest two tertiles for SAA as risk factors for poor survival. Subsequently, ApoA2 and SAA were stratified into three risk groups, a favorable risk group with no risk factors (ApoA2 > 309 mg/l and SAA < 19.2 ng/ml), an intermediate group with one risk factor (ApoA2 £ 309 mg/l or SAA ‡ 19.2 ng/ml) and a poor survival group with both risk factors (Table 3) . Accordingly, combining ApoA2 and SAA as a two-protein signature significantly predicted survival ( Figure 2A ; AIC = 732, R 2 = 0.23, P = 5.2 · 10 210 ). Median survival times for favorable, intermediate and poor prognostic groups were 58.3, 22.3 and 8.8 months with OS rates of 52%, 21% and 7%, respectively.
SAA and ApoA2 improve the MSKCC model
We examined the relation between several pretreatment features and survival with univariable Cox regression analysis [8] . Ten risk factors were significantly associated with survival (Table 1) . Poor KPS, elevated LDH, low hemoglobin, reduced albumin, presence of metastasis, two or more metastasis sites, histology, increased corrected calcium and the presence of lymph node metastasis contributed to poor survival. These results support earlier findings [8] . Prior nephrectomy, time from diagnosis to start treatment (TDT), presence of liver or skeletal metastasis and prior radiotherapy were not significant.
The currently used MSKCC risk model [2] was also prognostic for survival in our dataset ( Figure 2B ; AIC = 729, R 2 = 0.24, P = 1. (Table 4) . As indicated by Mekhail et al. [8] , only the number of metastasis sites was fitted in the analysis as this variable surpassed the independent predictors of liver, bone and lymph metastasis. Because radiotherapy had limited effect on survival, we excluded this parameter. Stepwise backward Cox PH regression modeling resulted in five independent risk factors: ApoA2, SAA, KPS, LDH and number of metastasis sites, providing a significantly improved proteinbased model (Table 3 ; AIC = 712, R 2 = 0.38 P = 1.4 · 10
210
). On the basis of these five risk factors, patients were categorized into three groups predicting good (zero or one risk factor), intermediate (two to three factors) and poor risk patients four or more factors). Kaplan-Meier curves showed powerfully discriminative outcomes ( Figure 2C ; AIC = 713, P = 4.3 · 10 211 ). The favorable risk group (27% of patients) had a median survival of 54.4 months, with 1-, 2-and 3-year survival rates of 90%, 71% and 58%, respectively. The intermediate risk group (54%) had a median survival of 12.7 months, with 1-, 2-and 3-year survival rates of 54%, 25% and 15%, respectively. The median survival of the poor risk group (19%) was 3.3 months, with 1-, 2-and 3-year survival rates of 18%, 5% and 0%, respectively.
comparison to MSKCC model
To interrogate the value of each of the models, we carried out AIC-based intermodel comparisons (Table 5) . Compared with the MSKCC model, 59 patients (52%) shifted between prognostic groups using the two-protein signature (Table 6 ). The largest modification was the reallocation of 36 patients from the intermediate MSKCC group to the poor prognostic group. The two-protein signature had similar survival prediction (AIC = 732) compared with the MSKCC model (AIC = 29).
Interestingly, applying our protein-based model, 43 patients (38%) switched risk groups, as compared with the MSKCC model ( Table 7) . Thirty-one patients classified into the favorable risk group by the protein-based model comprised 18 patients who were assigned to the intermediate group by the MSKCC model. Likewise, the MSKCC model allocated 11 patients to the favorable group and 6 patients to the poor Figure 1 . Zoomed-in regions of mass spectrometry profiles generated by the screening method surface-enhanced laser desorption ionization time-of-flight mass spectrometry. Two patients are shown with poor survival and two patients with long-term survival. The three depicted ion signals were validated by conventional quantification techniques. ApoA2 and SAA were both incorporated into novel protein-based risk models. ApoA2, apolipoprotein A2; SAA, serum amyloid alpha; TTR, transthyretin.
original article Annals of Oncology group, who were categorized into the intermediate group by the protein-based model. In our novel model, the poor risk group comprised 22 patients, of which 8 patients with poor survival had an intermediate risk according to the MSKCC model. As median survival times of the reallocated patients appropriately suited to their corresponding novel risk category, justified the switch in group of these patients, thereby improving the predictive accuracy of the risk model (Table 7) . Conclusively, our novel protein-based model was remarkably more discriminative and predictive than the MSKCC model (Table 5 ; AIC = 713 versus 729, respectively).
results in perspective: validation by bootstrapping
Ideally, we would verify these findings with an external dataset. However, since the samples used in this study were collected, new targeted therapies have replaced interferon-based treatment, making sera of a large similar patient cohort unavailable. Consequently, we decided to correct overestimation of our exploratory results with statistical bootstrapping to strengthen our findings [13] . For our two-protein signature and the novel protein-based prognostic model, R 2 was equal to 0.23 and 0.38, respectively. Both models were bootstrapped to correct optimism and showed comparable R 2 values equal to 0.22 and 0.34, respectively. With an optimism of, respectively, 0.01 and 0.04, we concluded that our proposed models proved to be internally valid, though the predictive accuracy was overestimated 10%.
discussion
This study shows that validated MS-based proteomic profiling is able to successfully and reproducibly identify proteins that predict patients' survival. Quantification of SAA and ApoA2 showed significant association with survival, revealing novel promising prognostic markers. These proteins improved patient prognostic categorization and indicate that they may be used either as a stand-alone test or as an extension to the commonly used MSKCC criteria. The latter yielded a novel protein-based model, comprising five factors, LDH, KPS, number of metastases, SAA and ApoA2, which enabled the classification of advanced RCC patients into three categories with distinct survival rates.
Classifying patients accurately into survival categories is crucial for clinical management, outcome evaluation and best supportive care. Equally, patient prognosis increasingly culminates in therapeutic choice, as the National Comprehensive Cancer Network guidelines recommend to treat patient with poor prognosis differently compared with intermediate and favorable risk groups [16] . The median OS Consequently, it is increasingly imperative to assign patients to best suitable therapeutic strategy by applying risk models. Our protein-based model shifted 38% patients to another risk group and indicated that these novel markers contribute to discriminate patients better in terms of prognosis than the MSKCC model. Finally, ApoA2 and SAA contribute to prognostic models and potentially improve existing risk models, thereby facilitating patient management.
SELDI-TOF MS is used as a cancer diagnostic device [17] and to predict relapse or therapeutic response [18] . Previously, ApoA2 and SAA have been independently described in several diagnostic studies being discriminatory between cancer patients and healthy controls. ApoA2 is a major apolipoprotein of high-density lipoproteins, modulating cholesterol transport [15] . ApoA2 levels are decreased in pancreatic [19] , colorectal [20] and ovarian cancer [21] . SAA is predominantly produced in the liver, macrophages and adipocytes and has proinflammatory and lipolytic functions [22] . SAA is upregulated in RCC [9, 10] , ovarian [23] , neuroblastoma [24] , prostate [18] , pancreatic [25] and hepatocellular cancer [26] . Our findings are supported in literature; SAA has been implicated as a marker to determine cancer dissemination and response to treatment, irrespective of the exact tumor type [27, 28] .
In general, cancer patients with metastatic disease become catabolic due to high-energy-consuming tumors and have loss of appetite, resulting in disturbed lipid metabolism, acute phase response, nutrient losses and altered hepatic protein production. Consequently, lipid and protein spectra will change. It is therefore tempting to speculate that these two proteins might also predict prognosis in other advanced malignancies. Accordingly, studies describe reduced ApoA2 levels in advanced cancers [21] and elevated SAA in disseminated cancers [18, 27, 28] , confirming that our twoprotein signature might be closely related to disease status and corresponding physiologic response of patients. Accordingly, SAA has very recently been described as highly predictive for progression-free survival and OS in large cohorts of RCC [29, 30] , breast cancer [31] and melanoma patients [32] . Therefore, we hypothesize that the quantity of these predictive serological proteins is an accurate reflection of actual disease status of patients and that changes over time will predict progressive disease regardless given therapy.
A limitation of our study is that samples were mainly collected before the approval of novel agents such as TKIs, mTOR and VEGF inhibitors. However, it seems that the risk factors constituting the MSKCC model are also applicable to these compounds [3, 4, 6] . As the MSKCC model is on the basis of a population of untreated mRCC patients receiving interferon-a treatment, there might be a bias in the results of comparing the MSKCC model with our novel prediction models, as 22% of patients in this study did not receive firstline therapy. Accordingly, 19 patients (17%) received TKIbased treatment as second-line treatment. TKI therapy has shown increased objective response rates in large cohorts of mRCC patients [3, 4] , which also might interfere with prognosis. At most, to position our exploratory findings in perspective and prevent premature conclusions, we have employed bootstrapping to correct for optimism of our data, showing just 10% overestimation. Nevertheless, we strongly indicate that these findings require further validation in a large multicenter prospective study in a homogenous untreated mRCC patient cohort, before being applied to practice. Thereby, we hope to conclude that these novel markers and corresponding models may improve assignment of patients to suitable risk-directed therapies.
The present study demonstrates that combining proteomicsbased screening with subsequent validation by protein quantification methods can yield novel biomarkers. The impact of these findings is highly clinically relevant. First, we have identified several novel proteins that predict survival from serum samples obtained and preserved at three different institutions. The heterogeneous manner in which these samples were collected indicates that the identified proteins are truly prognostic in a broad population of RCC patients. Secondly, when all quality controls are included, SELDI-TOF MS can be an effective method to screen for novel prognostic proteins. Thirdly, the prognostic value of three proteins was confirmed by commonly used protein quantification methods, supporting the reproducibility of the SELDI-TOF MS. Finally, our twoprotein signature seemed to outperform the prognostic value of the MSKCC model and may even be used as an independent prognostic stand-alone test. Most important, two of these serological proteins can be easily and inexpensively implemented in any well-equipped hospital in an objective, quantitative and noninvasive manner, improving the predictive accuracy of traditional clinical prognostic factors, yielding novel risk models. By reallocating about one in three patients into a different prognostic group, this model indicates to classify patients more accurately than the MSKCC model. If this is confirmed by subsequent prospective validation studies, these novel prognostic markers ApoA2 and SAA and their associated models have the major potential to contribute to more tailored therapeutic approaches in practice.
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